Mizuho Securities analyst Uy Ear maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $0.78.
Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Ocugen, and Satsuma Pharmaceuticals. According to TipRanks, Ear has an average return of 6.5% and a 30.51% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avrobio with a $5.33 average price target, which is a 581.93% upside from current levels. In a report released yesterday, BTIG also upgraded the stock to a Buy with a $4.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.29 and a one-year low of $0.56. Currently, Avrobio has an average volume of 351.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
Read More on AVRO: